In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

News headlines Vertex Pharmaceuticals is experiencing positive momentum driven by an upgrade from Wolfe Research and a strong outlook for its IgA nephropathy treatment. Analysts predict substantial ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...